18th week of 2014 patent applcation highlights part 44 |
Patent application number | Title | Published |
20140120049 | COMB POLYMERS FOR THE HAIR - Utilisation of (meth)acrylic comb copolymers with side chains of the hydroxy and alkoxy polyalkylene glycol type in which are present both ethylene oxide and propylene oxide links. These copolymers give a styling effect and an elimination of rinsing. The invention also relates to a cosmetic formulation containing such structures as well as a hair treatment process based on this formulation. | 2014-05-01 |
20140120050 | ANTI-DRANDRUFF HAIR CARE PRODUCTS WITH SELECTIVE ACTIVE INGREDIENTS AND A CATIONIC KERATIN - Hair treatment agents include selected cationic alkyloligoglucosides, alkyloligoglucosides, selected ester oils, and quaternary ammonium compounds as care-providing substances. | 2014-05-01 |
20140120051 | Skin Cosmetic - A skin cosmetic which exerts a feeling of ameliorating effect on skin wrinkles and sagging by application, and is free from uncomfortable feelings in use, such as stickiness, twisting of the cosmetic applied on the skin, and squeakiness. The cosmetic comprises an aqueous liquid of an anionic or amphoteric urethane resin dissolved or dispersed in water and wherein the anionic or amphoteric urethane resin is prepared by reacting (a) an isocyanate compound with (b) a polyol compound containing the following components (b-1) to (b-3) or the following components (b-1) to (b-4) and having a ratio of (b-1)/(b-2) of 0.15-3.0 (by mass, in terms of charge): [(b-1): cyclohexanedimethanol, (b-2): polypropylene glycol having a molecular weight of 1000-3000, (b-3): a compound having an active hydrogen and a carboxyl group in one molecule, (b-4): a compound having an active hydrogen and a tertiary amino group in one molecule.] | 2014-05-01 |
20140120052 | COMPOSITION AND METHOD FOR ARRESTING BLOOD FLOW AND FOR FORMING A PERSISTENT MICROBIAL BARRIER - A composition and method useful in promoting healing of a bleeding wound site. The composition preferably includes a substantially anhydrous acid form of a cation exchange resin, which when applied over blood, provides an antimicrobial against planktonic microorganisms and biofilms in the wound. The resin is also capable, when applied in sufficient quantities, of providing a continuing and persistent antimicrobial against planktonic microorganisms and biofilms through dehydration and ion exchange with cations present in the blood and other body fluids. When the resin has a concentration of at least 26 mg/ml, it provides a >3 log reduction in biological activity of MRSA, MRSE and Pseudomonas aeruginosa. | 2014-05-01 |
20140120053 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY - A therapeutic agent delivery system formed of a specific type of poly(ester amide) (PEA), a therapeutic agent, and a water miscible solvent is described herein. A method of delivering the therapeutic agent delivery system by delivering the therapeutic agent delivery system formed of a PEA polymer, a therapeutic agent, and a water miscible solvent to a physiological environment and separating the phase of the therapeutic agent delivery system to form a membrane from the polymer to contain the therapeutic agent within the physiological environment is also described. Additionally disclosed is a kit including a syringe and a therapeutic agent delivery system within the syringe. | 2014-05-01 |
20140120054 | CATIONIC MICELLES WITH ANIONIC POLYMERIC COUNTERIONS COMPOSITIONS THEREOF - The invention relates to polymer-micelle complex. The polymer-micelle complexes include a positively charged micelle selected from the group consisting of a monomeric quaternary ammonium compound, a monomeric biguanide compound, and mixtures thereof. The positively charged micelle is electrostatically bound to a water-soluble polymer bearing a negative charge. The polymer does not comprise block copolymer, latex particles, polymer nanoparticles, cross-linked polymers, silicone copolymer, fluorosurfactant, or amphoteric copolymer. The compositions do not form a coacervate, and do not form a film when applied to a surface. | 2014-05-01 |
20140120055 | ANIONIC MICELLES WITH CATIONIC POLYMERIC COUNTERIONS COMPOSITIONS THEREOF - The invention relates to a polymer-micelle complex. The polymer-micelle complexes include a negatively charged micelle that is electrostatically bound to a water-soluble polymer bearing a positive charge. The polymer does not comprise block copolymer, latex particles, polymer nanoparticles, cross-linked polymers, silicone copolymer, fluorosurfactant, or amphoteric copolymer. The compositions do not form a coacervate, and do not form a film when applied to a surface. | 2014-05-01 |
20140120056 | ANIONIC MICELLES WITH CATIONIC POLYMERIC COUNTERIONS METHODS THEREOF - The invention relates to a polymer-micelle complex, The polymer-micelle complexes include a negatively charged micelle that is electrostatically bound to a water-soluble polymer bearing a positive charge. The polymer does not comprise block copolymer, latex particles, polymer nanoparticles, cross-linked polymers, silicone copolymer, fluorosurfactant, or amphoteric copolymer. The compositions do not form a coacervate, and do not form a film when applied to a surface. | 2014-05-01 |
20140120057 | POLYMERS AND METHODS THEREOF FOR WOUND HEALING - Certain embodiments of the invention provide a copolymer having a backbone, wherein the backbone comprises a) one or more units that comprise a group that will yield a biologically active agent upon hydrolysis of the backbone; and b) one or more units of formula (II): | 2014-05-01 |
20140120058 | POLYMER CONJUGATED PROSTAGLANDIN ANALOGUES - The present invention relates in general to polymer-drug conjugates. In particular, the invention relates to polymer-drug conjugates wherein the conjugated drugs are selected from prostaglandins and substituted prostaglandins, to a method of delivering such prostaglandin drugs to a subject, to a sustained drug delivery system comprising the polymer-drug conjugates, to a method of preparing the polymer-drug conjugates, and to an implant comprising the polymer-drug conjugates. The polymer-drug conjugates may be useful for delivering prostaglandins and substituted prostaglandins for the treatment of glaucoma. | 2014-05-01 |
20140120059 | IMMUNITY INDUCING AGENT - Provided is a novel immunity-inducing agent useful as a therapeutic and/or prophylactic agent for cancer. The immunity-inducing agent comprises as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a), (b) and (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, which recombinant vector(s) is/are capable of expressing the polypeptide(s) in vivo: (a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 8, 10 and 12 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 85% to the polypeptide (a) and composed of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof. | 2014-05-01 |
20140120060 | TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING PI3 KINASE INHIBITORS - Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating rheumatoid arthritis or asthma. | 2014-05-01 |
20140120061 | ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION - The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse-resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the inventive compositions to the patient. Most preferably, the dosage form includes verapamil. These formulations have reduced potential for abuse. In another formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release. | 2014-05-01 |
20140120062 | THREE-DIMENSIONAL POROUS BIODEGRADABLE CELL SCAFFOLD - Disclosed are composites comprising water-soluble polymeric fibers dispersed in a biodegradable polymer matrix, as well as methods of making and using such composites. | 2014-05-01 |
20140120063 | NUTRITIONAL AND METABOLIC APPROACHES TO PREVENT EMERGENCE OF ENTERIC PATHOGENS - Antibiotic-associated enteric pathogens are shown to increase in mucosal carbohydrate availability that occur upon disruption of the competitive ecosystem. Transient post-antibiotic increase in monosaccharides liberated by the resident microbiota from host mucus provides a window of opportunity for these pathogens to expand to densities sufficient to induce self-promoting host inflammation. | 2014-05-01 |
20140120064 | GENERATION OF NEW PANCREATIC BETA CELLS - The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within. | 2014-05-01 |
20140120065 | PROTECTION FROM LETHAL IRRADIATION WITH MESENCHYMAL STROMAL CELLS - The present invention relates to the use of mesenchymal stromal cells (MSCs) for the treatment of supralethal radiation injury. | 2014-05-01 |
20140120066 | Cardiosphere Derived Cell Population and Methods of Use - Provided herein are compositions and methods for isolating and culturing cardiac progenitor cells, and for improved transplantation. | 2014-05-01 |
20140120067 | MUSCLE STEM CELL THERAPY FOR TREATMENT OF DYSPHAGIA - Described herein is a method for the treatment of dysphagia, comprising administering a therapeutically effective dose of an isolated muscle-derived stem cell population into a muscle involved in swallowing, such as tongue, pharynx, palate, and strap muscles. | 2014-05-01 |
20140120068 | SOLUTIONS, SYSTEMS AND METHODS FOR CELL, TISSUE AND ORGAN PRESERVATION - This disclosure provides solutions, systems, and methods for cell, tissue, and/or organ preservation. Some preservation solutions may include any combination of a balanced salt solution, electrolytes, antibiotic agents, antimycotic agents, protease inhibitors, anti-oxidants, simple sugars, starches impermeant ions, uric acid and/or amino acids. Some preservation solutions may also include hydrolyzed collagen. The preservation solutions including hydrolyzed collagen may be used alone or as part of a kit to preserve cells, tissue, or organs. The solution may also be used in connection with one or more medical procedures, for example organ transplantation. | 2014-05-01 |
20140120069 | Amphoteric Materials Based on Crosslinked Hyaluronic Acid, Method of Preparation Thereof, Materials Containing Entrapped Active Agents, Method of Preparation Thereof, and Use of Said Materials - The present invention describes novel amphoteric materials based on crosslinked hyaluronic acid, according to the general formula (I), and a method of preparation of said materials. Further, the invention relates to the material containing entrapped active agents (e.g. drugs, growth factors etc.) and a method of preparation thereof. Moreover, the present invention relates to the use of said materials for controlled release systems, in tissue engineering, wound dressing or tissue regeneration. | 2014-05-01 |
20140120070 | TESTIS SOMATIC CELL-DERIVED PLURIPOTENT STEM CELLS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR IMPOTENCE TREATMENT INCLUDING SAME - The present invention relates to testis somatic cell-derived pluripotent stem cells, and more particularly, to pluripotent adult stem cells which exhibit a positive immune reaction to both CD34 and CD73 and which are derived from testis somatic cells. The present invention further relates to a method for producing the testis somatic cell-derived pluripotent stem cells, and to a pharmaceutical composition including same for the treatment of erectile dysfunction. | 2014-05-01 |
20140120071 | RECOMBINANT FACTOR VIII HAVING ENHANCED STABILITY FOLLOWING MUTATION AT THE A1-C2 DOMAIN INTERFACE - The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed. | 2014-05-01 |
20140120072 | METHOD FOR AMPLIFYING NK CELLS - A technique is needed which can amplify NK cells in vitro and prepare optimum number of NK cells for the adoptive immunotherapy. | 2014-05-01 |
20140120073 | REDUCED COENZYME Q10 CRYSTAL HAVING EXCELLENT STABILITY - With respect to reduced coenzyme Q10, there has been no report about the presence of crystal polymorphism, and it has been considered that a conventionally obtained crystal form is only one form. The present invention relates to a reduced coenzyme Q10 crystal having an endothermic peak indicating melting at 54±2° C. during temperature rise at a rate of 5° C./min by differential scanning calorimetry (DSC), and/or to a reduced coenzyme Q10 crystal showing characteristic peaks at diffraction angles (2θ±0.2°) of 11.5°, 18.2°, 19.3°, 22.3°, 23.0° and 33.3° by powder X-ray (Cu—Kα) diffraction. The crystal form is a novel reduced coenzyme Q10 crystal which has a higher melting point and a lower solubility in a solvent, and is more excellent in stability than the conventionally known reduced coenzyme Q10 crystal. | 2014-05-01 |
20140120074 | ANTIMICROBIAL AGENTS - The present invention relates to a fusion protein comprising an endolysin with an amino acid sequence according to SEQ ID NO: 1 and fragments and/or derivatives thereof and an additional cationic or polycationic peptide, an amphipatic peptide, a sushi peptide, a defensin, a hydrophobic peptide or an antimicrobial peptide fused to said endolysin, fragment and/or derivative at the N- and/or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of staphylococcal infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said fusion protein for the treatment or prevention of staphylococcal contamination of foodstuff, of food processing equipment, of food processing plants, of feed for livestock animals, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said fusion protein. | 2014-05-01 |
20140120075 | Nanozyme Compositions and Methods of Synthesis and Use Thereof - Nanozymes and methods of use and synthesis thereof are provided. | 2014-05-01 |
20140120076 | EOSINOPHIL PEROXIDASE COMPOSITIONS AND METHODS OF THEIR USE - Eosinophil peroxidase compositions and methods of their use for killing and/or inhibiting the growth of susceptible microorganisms are provided. The compositions include an eosinophil peroxidase, a peroxide or peroxide source, and amino acids glycine, L-alanine, and L-proline. | 2014-05-01 |
20140120077 | Compositions and Methods for Safe Treatment of Rhinitis - Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis. | 2014-05-01 |
20140120078 | FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE - Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. | 2014-05-01 |
20140120079 | Compositions and Methods for Diagnosing and Treating Diabetic Micro Vascular Complications - Disclosed herein are compositions and methods for the identification of a subject at risk for developing microvascular complications associated with diabetes such as diabetic nephropathy and diabetic retinopathy. Also disclosed is a therapeutic target for the prevention and treatment of microvascular complications associated with diabetes. | 2014-05-01 |
20140120080 | Method for Treating or Preventing an Inflammatory Disease and/or an Autoimmune Disease - The present invention relates to a method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease in a patient, wherein the method comprises providing a pharmaceutical composition containing a therapeutically effective amount of soluble FcγR; administering said composition to a patient, followed by a safety period of several weeks, followed by a subsequent treatment cycle of at least two weekly administrations, wherein said therapeutically effective amount is effective to treat or prevent said disease in said patient. The present invention also provides a pharmaceutical composition in the form of a multiple-dosage-kit which contains sufficient amounts of administration doses of soluble FcγR for effectively treating or preventing inflammatory diseases and/or autoimmune diseases in a patient. | 2014-05-01 |
20140120081 | USE OF CARBON NANOMATERIALS WITH ANTIOXIDANT PROPERTIES TO TREAT OXIDATIVE STRESS - In some embodiments, the present invention provides methods of treating oxidative stress in a subject by administering a therapeutic composition to the subject. In some embodiments, the therapeutic composition comprises a carbon nanomaterial with anti-oxidant activity. In some embodiments, the anti-oxidant activity of the carbon nanomaterial corresponds to ORAC values between about 200 to about 15,000. In some embodiments, the administered carbon nanomaterials include at least one of single-walled nanotubes, double-walled nanotubes, triple-walled nanotubes, multi-walled nanotubes, ultra-short nanotubes, graphene, graphene nanoribbons, graphite, graphite oxide nanoribbons, carbon black, oxidized carbon black, hydrophilic carbon clusters, and combinations thereof. In some embodiments, the carbon nanomaterial is an ultra-short single-walled nanotube that is functionalized with a plurality of solubilizing groups. In some embodiments, the carbon nanomaterial is a polyethylene glycol functionalized hydrophilic carbon cluster (PEG-HCC). In some embodiments, the administered therapeutic compositions of the present invention may also include an active agent or targeting agent associated with the carbon nanomaterial. Additional embodiments of the present invention pertain to the aforementioned carbon nanomaterial compositions for treating oxidative stress. | 2014-05-01 |
20140120082 | MODULATION OF NKG2D - The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D. | 2014-05-01 |
20140120083 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS - Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders. | 2014-05-01 |
20140120084 | METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS - Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided. | 2014-05-01 |
20140120085 | Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy - An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene. | 2014-05-01 |
20140120086 | METHOD FOR PREPARATION OF A HIGH CONCENTRATION LIQUID FORMULATION OF AN ANTIBODY - The present invention provides a method for preparation of a high concentration liquid formulation (HCLF) of an antibody or a fragment thereof. The present invention also relates to a method for stabilizing an anti-CD20 antibody or a fragment thereof in a liquid pharmaceutical formulation. Furthermore, the present invention relates to a liquid pharmaceutical formulation of a veltuzumab antibody or a fragment thereof comprising at least 155 mg/mL of a veltuzumab antibody or a fragment thereof. | 2014-05-01 |
20140120087 | TRIAZOLOPYRIDINES - The present invention relates to triazolopyridine compounds of general formula (I): in which R | 2014-05-01 |
20140120088 | AGENTS FOR THE TREATMENT OF TUMORS - The invention relates to the treatment of patients with a brain tumor or neoplastic meningitis, by the use of an agonist of the TLR9 receptor in combination with an anti-angiogenic product. | 2014-05-01 |
20140120089 | ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR - The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention. | 2014-05-01 |
20140120090 | CROSS-LINKING POLYPEPTIDE THAT INDUCES APOPTOSIS - The disclosure relates to a polypeptide comprising at least four domains specifically binding to a certain MHC peptide complex, the domains separated by linker amino acid sequences, thereby providing each domain with the capability to bind a separate MHC peptide complex, to a nucleic acid encoding for such a polypeptide, to a vector comprising such a nucleic acid, to a host cell for expression of such a polypeptide, to a pharmaceutical composition comprising such a polypeptide, and to a kit of parts comprising at least two polypeptides according to the disclosure. | 2014-05-01 |
20140120091 | FUSION PROTEINS FOR THERAPY OF AUTOIMMUNE AND CARDIOVASCULAR DISEASE - The present invention provides improved fusion proteins for therapy of autoimmune and cardiovascular disease. | 2014-05-01 |
20140120092 | Antigen Binding Proteins that Bind ErbB3 - There is disclosed compositions and methods relating to or derived from anti-ErbB3 antibodies. More specifically, there is disclosed fully human antibodies that bind ErbB3, ErbB3-binding fragments and derivatives of such antibodies, and ErbB3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having ErbB3 related disorders or conditions, including various inflammatory disorders and various cancers. | 2014-05-01 |
20140120093 | Anti-Infective Binding Proteins that Bind AIP2 - There is disclosed compositions and methods relating to or derived from anti-AIP2 antibodies. More specifically, there is disclosed fully human antibodies that bind AIP2, AIP2-binding fragments and derivatives of such antibodies, and AIP2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having AIP2 related disorders or conditions. There is also disclosed a method to treat | 2014-05-01 |
20140120094 | Use of IL-20 Antagonists for Treating Liver Diseases - Reducing liver fibrosis in a subject having or being suspected of having a liver disease using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway. | 2014-05-01 |
20140120095 | BISPECIFIC BINDING MOLECULES FOR ANTI-ANGIOGENESIS THERAPY - Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a DII4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and DII4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same. | 2014-05-01 |
20140120096 | BISPECIFIC IGG ANTIBODIES AS T CELL ENGAGERS - Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided. | 2014-05-01 |
20140120097 | GENERATION OF NEW PANCREATIC BETA CELLS - The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within. | 2014-05-01 |
20140120098 | FIBCD1 FOR THE PREVENTION AND TREATMENT OF DISEASES - The present invention relates to methods and compositions for the treatment and/or prevention of diseases such as allergic diseases and inflammatory bowel diseases comprising one or more FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof and optionally one or more non-FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof; as well as the use of such pharmaceutical composition for the prevention and/or treatment of diseases such as allergic diseases and inflammatory bowel diseases. FIBCD1 is herein defined as either a transmembrane receptor, the corresponding DNA or the correspond mRNA as defined by SEQ ID No. 1, 2 and 3 as well as homologous thereof. | 2014-05-01 |
20140120099 | TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN - The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression. | 2014-05-01 |
20140120100 | COMPOSITIONS AND METHODS FOR PREVENTING ERYTHROPOIETIN-ASSOCIATED HYPERTENSION - The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (Epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of Epo treatment. The invention provides a method of treating anemia in a mammal involving: administering erythropoietin (Epo) to the mammal; and administering to the mammal an agent selected from a soluble Epo-binding protein (Epo-bp), a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor, and a combination thereof. The invention also provides a method of reducing hypertension in a mammal receiving Epo, and pharmaceutical compositions containing a soluble Epo-bp and/or a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor. | 2014-05-01 |
20140120101 | Anti-IL12Rbeta1 Antibodies And Their Use In Treating Autoimmune And Inflammatory Disorders - The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders. | 2014-05-01 |
20140120102 | THERAPEUTIC AND DIAGNOSTIC METHODS RELATED TO LYSYL OXIDASE-LIKE 2 (LOXL2) - Provided are therapeutic, diagnostic, and prognostic methods for disease, including diseases associated with fibrosis and cancer using agents that bind to, inhibit, and/or detect lysyl oxidase-like 2 (LOXL2), and agents, compositions, kits, assay systems, and devices for use with such methods. | 2014-05-01 |
20140120103 | ANTI-CD40 ANTIBODIES AND METHODS OF USE - The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases. | 2014-05-01 |
20140120104 | CADHERIN-11 EC1 DOMAIN ANTAGONISTS FOR TREATING INFLAMMATORY JOINT DISORDERS - The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumaotid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist. | 2014-05-01 |
20140120105 | THERAPEUTIC TARGETING OF FICOLIN-3 - The present Invention relates to novel antibodies against Ficolin-3, which antibodies inhibit complement activation. The invention further relates to the use of anti-Ficolin-3 antibodies in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to nucleic acid molecules encoding such antibodies, vectors and host cells used in the production of the antibodies. | 2014-05-01 |
20140120106 | Stimulation of Arterial Collateral Growth and Lymphogenesis - Compositions and method for stimulating and controlling arteriogenesis and lymphatic vasculature by preventing and/or reducing the cellular interaction between RAF1 and AKT have been developed. The compositions include molecules that increase the bioavailability of non-phosphorylated RAF1, for example, the RAF1 Ser259 to Ala259 mutant in (RAF1 S259A), and AKT1 inhibitory molecules. Defects, disorders or diseases of insufficient blood or lymphatic vasculature are treated by administering to a patient in need thereof, a pharmaceutical composition comprising a molecule specifically blocking RAF1-AKT crosstalk in a pharmaceutically acceptable carrier or excipient in an amount effective to enhance the growth of blood or lymphatic vasculature in the patient. Compositions can be administered by injection or by controlled or sustained release devices, coating on devices or implants, microparticles, bulking agents or depots, or other techniques providing controlled or sustain release over a period of time effective to induce blood or lymphatic vasculature growth as desired. | 2014-05-01 |
20140120107 | GENES OF AN OTITIS MEDIA ISOLATE OF NONTYPEABLE HAEMOPHILUS INFLUENZAE - The invention relates to the polynucleotide sequence of a nontypeable stain of | 2014-05-01 |
20140120108 | MUTANT PTP ALPHA GENE GROUP IN MALIGNANT TUMORS AND PRODUCTION METHOD - A group of mutant PTPαgenes in malignant tumor are provided, which are ΔPTPα245, ΔPTPα652 and ΔPTPα445 respectively. The mutation includes insertion of 95 new nucleotides after nucleotide at position 711, deletion of nucleotides at position 1015-1437, and deletion of nucleotides at position 1015-1437 accompanied by insertion of 340 nucleotides after coding exon at position 1681 and fusion of 26 new amino acids at C-terminal. The group of mutant PTPαgenes in different types of malignant tumor disclosed in the present application have not been reported all over the world so far. The detection method of using PTPαmutant genes is useful in exactly diagnosing malignant tumor, developing new anti-tumor drugs, and targeted treatment at molecular pathologic level. | 2014-05-01 |
20140120109 | Human Antibodies to Human TNF-Like Ligand 1A (TL1A) - A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation. | 2014-05-01 |
20140120110 | ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 - The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production. | 2014-05-01 |
20140120111 | TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTIONS USING ANTAGONISTS OF SGK1 ACTIVITY - The present invention provides novel methods for treating Th2-mediated immune disorders and enhancing Th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (SGK1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught. The present invention also provides methods for augmenting the treatment of subjects having viral or parasitic infections, or which have cancerous tumors. | 2014-05-01 |
20140120112 | THERAPEUTICS FOR AGE-RELATED MACULAR DEGENERATION - The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD. | 2014-05-01 |
20140120113 | HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUSES OF PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUSES - The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses. | 2014-05-01 |
20140120114 | Antibodies to EphA3 - The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. | 2014-05-01 |
20140120115 | ANTIBODIES THAT ARE CROSS-REACTIVE FOR MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AND D-DOPACHROME TAUTOMERASE (D-DT) - The present disclosure relates to antigen-binding moieties that specifically bind to MIF and D-DT and compositions and methods of use thereof. | 2014-05-01 |
20140120116 | TREATMENT OF CANCER USING SMAD3 INHIBITOR - The present invention resides in the discovery that Smad3, a key downstream mediator of TGF-β signaling, plays a critical role in development and progression of cancer. Thus, this application provides for a novel method of treating cancer by inhibiting Smad3 signaling, such as through administration of SIS3, an inhibitor of Smad3. Further provided are compositions and kits useful for treating cancer by way of inhibiting Smad3 signaling. | 2014-05-01 |
20140120117 | TREATMENT OF TUMORS USING SPECIFIC ANTI-L1 ANTIBODY - The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment. | 2014-05-01 |
20140120118 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - A compound which is selected from A: | 2014-05-01 |
20140120119 | PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES - The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm | 2014-05-01 |
20140120120 | COMPOSITION FOR TREATING DIABETES COMPRISING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE - The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability. | 2014-05-01 |
20140120121 | MEDICINAL TREATMENT OF ATOPIC INFLAMMATORY DISEASES - The methods disclosed herein relate to the treatment of atopic inflammatory disorders, such as dermal or pulmonary atopic inflammatory disorders, in humans, by administering a therapeutically effective amount of ractopamine. | 2014-05-01 |
20140120122 | METHOD FOR MONITORING VACCINE RESPONSE USING SINGLE CELL NETWORK PROFILING - The present invention provides methods for determining safety and efficacy of a vaccine by monitoring cellular pathways prior to and after vaccine treatment using single cell network profiling | 2014-05-01 |
20140120123 | FUSION PROTEINS FOR THE TREATMENT OF ALLERGIC DISEASES - The present invention relates to a fusion protein comprising a first peptide and a second peptide linked together with a linker, wherein the first peptide is an allergen and the second peptide is a targeting unit and the second targeting unit peptide is a FGL-2 C-terminal peptide according to SEQ ID no 1. Provided herein are also uses of said fusion protein as a vaccine for treating shrimp allergy, as well as a vaccine composition and methods of its production. | 2014-05-01 |
20140120124 | CELL CAPABLE OF EXPRESSING EXOGENOUS GITR LIGAND - Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject. | 2014-05-01 |
20140120125 | VACCINE COMPOSITION COMPRISING AN INACTIVATED CHIKUNGUNYA VIRUS STRAIN - A vaccine composition for prophylaxis and treatment of Chikungunya virus infections is disclosed which is capable of conferring immunity against any genotypic variants of the Chikungunya virus. More particularly the invention discloses particular nucleotide sequences and their translated proteins thereof, which may be expressed as Virus Like Particles which for use as a vaccine antigens against Chikungunya virus infections. The compositions disclosed in this invention are also protective against any genotypic variants of the Chikungunya virus which may be propagated by any suitable vector of the disease including | 2014-05-01 |
20140120126 | COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS - The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses. | 2014-05-01 |
20140120127 | RECOMBINANT HCV E2 GLYCOPROTEIN - The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof. | 2014-05-01 |
20140120128 | USE OF YSCF, TRUNCATED YSCF AND YSCF HOMOLOGS AS ADJUVANTS - An antigenic composition comprising an antigen and an effective adjuvant, the adjuvant comprising isolated or recombinant YscF, a YscF fragment, truncated YscF (trYscF), or homologs thereof. A method of inducing an enhanced immune response comprising administering an antigen and an effective adjuvant comprising isolated or recombinant YscF, a YscF fragment, trYscF, or homologs thereof. An antigenic composition produced by a process comprising providing a host cell with an expression vector containing a nucleotide sequence encoding YscF, a YscF fragment, trYscF, or YscF homolog capable of acting as an adjuvant; expressing the nucleotide sequence in the host cell to produce the protein; and mixing the collected protein with a suitable excipient. | 2014-05-01 |
20140120129 | CHLAMYDIA ANTIGENS - antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as | 2014-05-01 |
20140120130 | Extraction Technology of Xiao-Yao-Drink - An extraction technology of a Xiao-yao-drink includes a medicine preparing step of preparing herbal medicines, a pulverizing step of pulverizing the herbal medicines to produce medicinal solid particles, a liquid extracting step of adding the medicinal solid particles into an extraction liquid to dissolve the medicinal solid particles in the extraction liquid, an ultrasonic extraction step of impacting the medicinal solid particles in the extraction liquid by concentrated ultrasonic waves to crush the medicinal solid particles into medicinal molecules, and a centrifugal filtering step of filtering the medicinal molecules from the extraction liquid by a strainer cloth to produce a medicinal extract which constructs a Xiao-yao-drink product. Thus, the extraction technology uses an ultrasonic extraction procedure to crush the medicinal solid particles into medicinal molecules by concentrated ultrasonic waves to efficiently increase the active component of the herbal medicine. | 2014-05-01 |
20140120131 | COMPOSITION COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS - Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle. | 2014-05-01 |
20140120132 | LENTIVIRAL VECTORS CONTAINING AN MHC CLASS I PROMOTER - The present invention relates to the insertion of a promoter sequence from an MHC class I gene promoter into a lentiviral vector in order to direct the transcription of a transgene, which preferably encodes an immunogenic polypeptide to be expressed in a mammalian cell host, preferably APC (DCs). The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses. | 2014-05-01 |
20140120133 | Vaccine Against African Horse Sickness Virus - The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions. | 2014-05-01 |
20140120134 | LIVE, ORAL VACCINE FOR PROTECTION AGAINST SHIGELLA DYSENTERIAE SEROTYPE 1 - The invention relates to | 2014-05-01 |
20140120135 | AQUEOUS COMPOSITION COMPRISING A BIOLOGICAL ANTIGEN AND AN ACRYLIC ACID POLYMER - The current invention pertains to an aqueous composition containing a biological antigen and an acrylic acid polymer, wherein the composition comprises an electrolyte to provide an osmolarity higher than the osmolarity of a 0.9% (w/v) sodium chloride solution in water. The invention also pertains to the acrylic acid polymer for use in a one shot vaccine against porcine circo virus 2 (PCV2) and optionally | 2014-05-01 |
20140120136 | MIR-155 ENHANCEMENT OF CD8+ T CELL IMMUNITY - The present invention provides novel methods of enhancing CD8+ T cell mediated immunity (also referred to as “CD8+ T cell immunity”) in a patient having a diseased state. In particular, the present invention provides for the enhanced expression of miR-155 in a population of patient specific T cells through the introduction of a nucleic acid molecule encoding a miR-155 transcript or a nucleic acid molecule encoding a chimeric antigen receptor and a miR-155 transcript into those cells, followed by the reintroduction of the T cells into the patient. The present invention also provides methods of enhancing the expansion of these T cells relative to control cells. Increased expansion of CD8+ T cells following enhanced miR-155 expression is directly related to enhanced CD8+ T cell immunity. The present invention further provides methods of enhancing anti-cancer immunity in a patient through the increased expression of miR-155 in patient specific T cells. | 2014-05-01 |
20140120137 | LACTIC ACID BACTERIA AND THEIR USE IN SWINE DIRECT-FED MICROBIALS - TRFs useful for identifying strains of interest are provided. A method of identifying one or more strain that can be used as a direct-fed microbial is also provided. One or more strain identified by the method is additionally provided. A method is also provided for administering to an animal an effective amount of the one or more strain. Additionally provided is an isolated strain chosen from at least one of | 2014-05-01 |
20140120138 | PHARMACEUTICAL COMPOSITIONS COMPRISING ATTENUATED PLASMODIUM SPOROZOITES AND GLYCOLIPID ADJUVANTS - Disclosed herein are pharmaceutical compositions comprising | 2014-05-01 |
20140120139 | METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE - Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided. | 2014-05-01 |
20140120140 | System for Dissolution of a Tablet or Granulate in a Stream of Water - The application discloses a discus-shaped unit of a tablet or granulates which contain abrasive media, to be dissolved into a stream of water. Tablet or granulates are encased in a flexible, but inherently stable mesh of filaments for to enhance dissolution, avoid clogging nozzles and ease disposal of residues. | 2014-05-01 |
20140120141 | PEPTIDES USEFUL IN THE TREATMENT AND CARE OF THE SKIN AND MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Peptides of general formula (I), their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use for the treatment and/or care of conditions, disorders and/or diseases of the skin and/or mucous membranes. | 2014-05-01 |
20140120142 | Dental Anti-Hypersensitivity Composition and Method - The present invention relates to compositions and methods for calcifying dental tissue, e.g., preventing or treating dental hypersensitivity. An oral composition of arginine bicarbonate and calcium carbonate promotes the formation of dentinal tubule plugs aided by combining calcium and phosphate in the fluid. In a specific example, an arginine bicarbonate/calcium carbonate mixture blocked dentinal tubules in a model system. In addition to treating dentinal sensitivity, the compositions and methods of the invention provide for calcifying exposed tooth pulp, calcifying the base or all of a pit or fissure in a tooth, and treating a carious lesion. | 2014-05-01 |
20140120143 | KIT FOR PERSONALIZING THE COLOR OF A TOPICAL SKIN COMPOSITION - Disclosed is a kit for preparing a colored topical skin composition, the kit comprising a first composition comprising an aqueous continuous phase comprising at least 50% by weight of water and a discontinuous phase comprising titanium dioxide or zinc oxide or a combination thereof in an amount sufficient to impart a white color appearance to the first composition, wherein the titanium dioxide or zinc oxide is suspended within the aqueous continuous phase, and wherein the color of the first composition is white and a second composition in the form of a water-dissolvable film, wherein the film has a color other than white, wherein the second composition is capable of dissolving within the first composition and imparting a color other than white to the first composition when the first and second compositions are mixed together. | 2014-05-01 |
20140120144 | Thin Film Supporting Hyaluronic Acid Or Derivative Thereof And Thin Film Cosmetic - The present invention provides a thin film having an excellent manageability, moisture-retaining effect, and unevenness correction effect and a thin film cosmetic. The thin film of the present invention is a laminate of (a) a base film supporting hyaluronic acid or a derivative thereof and (b) a carrier, wherein the thickness of film (a) is 10 to 500 nm. | 2014-05-01 |
20140120145 | Formula and Process for Crosslinking Antimicrobials to Textiles - A process is described herein for applying antimicrobials to substrates such as fabrics. An antimicrobial-binder mixture is provided that includes an antimicrobial and a binder that includes guar gum in an aqueous solution, which is applied to the substrate. Once the substrate is cured, spikes formed by the antimicrobial are disposed on the fabric and function to rupture membranes of infectious agents. | 2014-05-01 |
20140120146 | MEDICAL ANTIMICROBIAL COMPOSITION AND MEDICAL DEVICE COMPRISING THE SAME - A medical antimicrobial composition includes a siloxanyl structure-containing polymer and an ammonium group-containing polymer, which is excellent in transparency, flexibility and mechanical properties, and also excellent in adhesion to a base resin with good mechanical properties, particularly to a silicone resin. The medical antimicrobial composition includes an ammonium group-containing polymer compound (A) dispersed in a siloxanyl structure-containing polymer (B) and a medical device comprising the medical antimicrobial composition. | 2014-05-01 |
20140120147 | ISOXAZOLINE DERIVATIVES AS PESTICIDES - The invention relates to new isoxazoline compounds of formula | 2014-05-01 |
20140120148 | ANTIMICROBIAL MATERIAL AND USES THEREOF - An antimicrobial material, antimicrobial devices and method of reducing or eliminating microorganisms from a fluid susceptible to contain microorganisms is presented. The antimicrobial material is comprised of a porous activated ceramic substrate; a titanium dioxide layer covalently bound to the ceramic substrate; and a silver salt layer covalently bound to the titanium oxide layer. This antimicrobial material is used in the antimicrobial devices and methods to reduce or eliminate microorganisms in fluid. | 2014-05-01 |